Genmab (GNMSF)
(Delayed Data from OTC)
$246.61 USD
+9.10 (3.83%)
Updated Sep 24, 2024 03:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Genmab A/S [GNMSF]
Reports for Purchase
Showing records 1 - 20 ( 20 total )
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
1Q19 DARZALEX Sales Cast Doubt on Guidance, as We Have Anticipated - We Estimate a 3.80 Q1 EPS; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
We Are Optimistic Regarding a Rapid Approval Pathway for a DARZALEX plus Revlimid Maintenance Regimen; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
Pivotal Phase 2 Tisotumab Vedotin Trial Enrollment Completion an Incremental Positive; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
Front-Line Setting Expansion Efforts Continue with FDA Submission of CASSIOPEIA Trial-Based Application; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
EMA Application Submitted for DARZALEX''s Label Expansion in Transplant-Ineligible Multiple Myeloma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
RTOR Pathway Could Expedite DARZALEX Approval in Transplant-Ineligible Multiple Myeloma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
Phase 3 COLUMBA Trial Meets Co-Primary Endpoints, According to Expectations; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
FY2018 Financial Results Reported; Continued Bullish Outlook for DARZALEX; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
DARZALEX Split Dosing Regimen Approved - COLUMBA Trial Should Provide Differentiation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
We Remain Confident on DARZALEX as Competition Heats Up; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
MorphoSys Patents Declared Invalid; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
DARZALEX Reach Slated to Broaden; Modulating Near-Term Estimates; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
ASH Data Reinforces DARZALEX''s Front-Line Position in Multiple Myeloma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
GEN1046 and GEN1042 SITC Posters Highlight Diverse Portfolio; DARZALEX Outlook Positive; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
Dexamethasone Emerges as New 1L Standard of Care; Reiterate Buy.
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
Steady 3Q18 WW DARZALEX Sales Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
Tisotumab Vedotin Remains an Underappreciated Asset; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S
Industry: Medical - Biomedical and Genetics
Driven by DARZALEX; Initiating at Buy and DKK 1,600 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
|